Skip to main content
OpenTrials

Clinical trial condition

Marginal Zone Lymphoma

Explore clinical trials studying Marginal Zone Lymphoma. Study availability and eligibility vary by location and protocol.

115 public trials 42 recruiting studies
Refine in advanced search Browse all conditions

Marginal Zone Lymphoma trial results

Active, not recruiting

A Phase 3 Study to Assess Efficacy and Safety of Tafasitamab Plus Lenalidomide and Rituximab Compared to Placebo Plus Lenalidomide and Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma or Marginal Zone Lymphoma.

NCT04680052

Conditions
Follicular Lymphoma, Hemic and Lymphatic Diseases, Immune System Diseases, +11 more
Locations
  • John Muir Health Clinical Research Center Concord, California, United States
  • Marin Cancer Care Greenbrae, California, United States
  • The Oncology Institute of Hope and Innovation Pasadena, California, United States
  • Sharp Memorial Hospital San Diego, California, United States
View all 261 locations
View Trial Details
Active, not recruiting

19(T2)28z1xx Chimeric Antigen Receptor (CAR) T Cells in People With B-Cell Cancers

NCT04464200

Conditions
Blood Protein Disorders, Burkitt Lymphoma, Burkitt's Lymphoma, +41 more
Locations
  • Memorial Sloan Kettering at Basking Ridge (Limited Protocol Activities) Basking Ridge, New Jersey, United States
  • Memorial Sloan Kettering Monmouth (Limited Protocol Activities) Middletown, New Jersey, United States
  • Memorial Sloan Kettering Bergen (Limited Protocol Activities) Montvale, New Jersey, United States
  • Memorial Sloan Kettering Cancer Commack - Suffolk (Limited Protocol Activities) Commack, New York, United States
View Trial Details
Active, not recruiting

FDG PET Evaluation for Marginal Zone Lymphoma and Its Prognostic Role

NCT04333524

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +9 more
Locations
  • CHU de Dijon Dijon, France
  • Saint Louis Hospital Paris, France
  • IUCT Oncopole Toulouse Toulouse, France
  • ASO SS. Antonio e Biagio e C. Arrigo Alessandria, AL, Italy
View all 25 locations
View Trial Details
Active, not recruiting

A Study of Ibrutinib With Rituximab in People With Untreated Marginal Zone Lymphoma

NCT04212013

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +9 more
Locations
  • George Washington Cancer Center Washington D.C., District of Columbia, United States
  • Moffitt Cancer Center Tampa, Florida, United States
  • Mayo Clinic Cancer Center Rochester, Minnesota, United States
  • Memorial Sloan Kettering Basking Ridge Basking Ridge, New Jersey, United States
View Trial Details
Active, not recruiting

A Phase II Study Using Rituximab Plus Venetoclax in the Front Line Treatment of Marginal Zone Lymphoma

NCT04416451

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +9 more
Locations
  • City of Hope Cancer Center (Data collection only) Duarte, California, United States
  • Memorial Sloan Kettering Basking Ridge (All Protocol Activities) Basking Ridge, New Jersey, United States
  • Memorial Sloan Kettering Monmouth (All protocol activities) Middletown, New Jersey, United States
  • Memorial Sloan Kettering Bergen (All protocol Activities) Montvale, New Jersey, United States
View Trial Details
Active, not recruiting

A Study of Nemtabrutinib (MK-1026) in Participants With Relapsed or Refractory Hematologic Malignancies (ARQ 531-101/MK-1026-001)

NCT03162536

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Chronic Disease, +41 more
Locations
  • Mayo Clinic Hospital ( Site 0140) Scottsdale, Arizona, United States
  • UCLA Hematology & Oncology ( Site 0017) Los Angeles, California, United States
  • Colorado Blood Cancer Institute ( Site 0225) Denver, Colorado, United States
  • University of Michigan ( Site 0018) Ann Arbor, Michigan, United States
View Trial Details

Related conditions